Performance of EXEL Exelixis | 16.4% in 12m
Compare EXEL with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Exelixis with its related Sector/Index XBI
Performance Duell EXEL vs XBI
| TimeFrame | EXEL | XBI |
|---|---|---|
| 1 Day | -6.54% | 3.20% |
| 1 Week | -7.53% | 4.04% |
| 1 Month | -7.41% | -6.95% |
| 3 Months | 0.80% | -1.84% |
| 6 Months | 4.31% | 29.21% |
| 12 Months | 16.4% | 6.43% |
| YTD | -8.38% | -3.21% |
| Rel. Perf. 1m | 0.39 | |
| Rel. Perf. 3m | -0.38 | |
| Rel. Perf. 6m | -1.62 | |
| Rel. Perf. 12m | 1.28 |
Is Exelixis a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Exelixis (NASDAQ:EXEL) is currently (May 2024)
ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 47.47 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EXEL as of May 2024 is 20.19. This means that EXEL is currently overvalued and has a potential downside of -7.93% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EXEL as of May 2024 is 20.19. This means that EXEL is currently overvalued and has a potential downside of -7.93% (Sold with Premium).
Is EXEL a buy, sell or hold?
- Strong Buy: 9
- Buy: 5
- Hold: 5
- Sell: 2
- Strong Sell: 0
Values above 0%: EXEL is performing better - Values below 0%: EXEL is underperforming
Compare EXEL with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -6.53% | -3.23% | -14.92% | -5.72% |
| US NASDAQ 100 | QQQ | -6.36% | -2.14% | -14.23% | -15.26% |
| US Dow Jones Industrial 30 | DIA | -6.09% | -3.30% | -10.65% | 2.96% |
| German DAX 40 | DBXD | -6.65% | -5.41% | -15.70% | 2.98% |
| UK FTSE 100 | ISFU | -9.02% | -9.30% | -11.42% | 7.76% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -10.36% | -7.98% | 2.90% | 29.10% |
| Hongkong Hang Seng | HSI | -11.59% | -10.48% | 5.86% | 35.69% |
| Japan Nikkei 225 | EXX7 | -6.77% | -1.39% | -10.46% | -2.52% |
| India NIFTY 50 | INDA | -8.30% | -9.20% | -16.45% | -11.26% |
| Brasil Bovespa | EWZ | -8.05% | -5.27% | -0.89% | -1.43% |
EXEL Exelixis vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -4.73% | -2.90% | -15.97% | -15.99% |
| Consumer Discretionary | XLY | -7.72% | -3.03% | -9.48% | -3.69% |
| Consumer Staples | XLP | -6.33% | -6.45% | -8.02% | 16.81% |
| Energy | XLE | -3.21% | -4.17% | -5.90% | 3.32% |
| Financial | XLF | -5.68% | -3.76% | -20.69% | -7.74% |
| Health Care | XLV | -7.33% | -3.39% | -9.25% | 9.98% |
| Industrial | XLI | -6.82% | -4.39% | -19.59% | -6.15% |
| Materials | XLB | -8.38% | -3.55% | -14.00% | 3.51% |
| Real Estate | XLRE | -6.36% | -0.64% | -6.43% | 16.17% |
| Technology | XLK | -5.63% | -0.42% | -12.34% | -13.32% |
| Utilities | XLU | -8.68% | -10.87% | -9.50% | 15.38% |
| Aerospace & Defense | XAR | -9.19% | -5.81% | -13.98% | -3.48% |
| Biotech | XBI | -11.57% | -0.46% | -24.90% | 10.01% |
| Homebuilder | XHB | -7.10% | -0.19% | -34.62% | -29.51% |
| Retail | XRT | -5.82% | 1.74% | -18.28% | -1.95% |
Does Exelixis outperform its market, is EXEL a Sector Leader?
Yes, over the last 12 months Exelixis (EXEL) made 16.44%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.43%.
Over the last 3 months EXEL made 0.80%, while XBI made -1.84%.
Yes, over the last 12 months Exelixis (EXEL) made 16.44%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.43%.
Over the last 3 months EXEL made 0.80%, while XBI made -1.84%.
| Period | EXEL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -7.41% | -6.95% | -4.18% |
| 3 Months | 0.80% | -1.84% | 2.60% |
| 12 Months | 16.44% | 6.43% | 22.16% |